文献速递复苏、休克与脓毒症重症综合管理与镇静镇痛

去甲肾上腺素与血管加压素:脓毒性休克中应先停用哪种血管活性药?一项Meta分析

Norepinephrine vs Vasopressin: Which Vasopressor Should Be Discontinued First in Septic Shock? A Meta-Analysis.
PubMed 文献 · Shock · 2020-01-01
一句话结论成人脓毒性休克联用血管加压素与去甲肾上腺素时,先停血管加压素可能增加低血压发生率(OR 0.3,95%CI 0.10–0.86),但与死亡率或ICU住院时间无关。

本Meta分析纳入1项前瞻性随机对照试验和7项回顾性队列研究,比较脓毒性休克成人患者联用去甲肾上腺素(NE)和血管加压素(VP)时,先停NE还是先停VP对低血压发生率、总体死亡率、ICU死亡率和ICU住院时间的影响。结果显示,先停NE组低血压发生率显著低于先停VP组(OR 0.3,95%CI 0.10–0.86,P=0.02;I=91%)。两组总体死亡率(OR 1.28,95%CI 0.77–2.10,P=0.34)和ICU死亡率(OR 0.99,95%CI 0.74–1.34,P=0.96)无显著差异;5项研究评估的ICU住院时间也无统计学差异(均数差1.35,95%CI -2.05–4.74,P=0.44)。亚组分析提示,在皮质类固醇使用率低的患者中,先停VP与低血压显著相关(OR 0.18,95%CI 0.04–0.78,P=0.02)。试验序贯分析表明当前证据不足以得出结论(所需信息量=11 821)。

要点

  • 在成人脓毒性休克联用NE和VP的患者中,先停NE组低血压发生率显著低于先停VP组(OR 0.3,95%CI 0.10–0.86,P=0.02;I=91%)。
  • 两组总体死亡率无显著差异(OR 1.28,95%CI 0.77–2.10,P=0.34),ICU死亡率也无显著差异(OR 0.99,95%CI 0.74–1.34,P=0.96)。
  • 5项研究评估的ICU住院时间在两种停药顺序间无统计学差异(均数差1.35,95%CI -2.05–4.74,P=0.44)。
  • 亚组分析提示,在皮质类固醇使用率低的患者中,先停VP与低血压显著相关(OR 0.18,95%CI 0.04–0.78,P=0.02)。
  • 试验序贯分析表明当前证据不足以得出结论(所需信息量=11 821),作者认为需更大样本量的前瞻性研究。

适用人群与场景

  • 接受去甲肾上腺素(NE)与血管加压素(VP)联合治疗的成人脓毒性休克患者。

研究设计与关键结果

  • 研究类型:Meta分析,纳入1项前瞻性随机对照试验和7项回顾性队列研究。
  • 主要终点:先停NE组低血压发生率显著低于先停VP组(OR 0.3,95%CI 0.10–0.86,P=0.02;I=91%)。
  • 总体死亡率:两组无显著差异(OR 1.28,95%CI 0.77–2.10,P=0.34)。
  • ICU死亡率:两组无显著差异(OR 0.99,95%CI 0.74–1.34,P=0.96)。
  • ICU住院时间:5项研究评估,两组无统计学差异(均数差1.35,95%CI -2.05–4.74,P=0.44)。
  • 亚组分析:在皮质类固醇使用率低的患者中,先停VP与低血压显著相关(OR 0.18,95%CI 0.04–0.78,P=0.02)。
  • 试验序贯分析:当前证据不足以得出结论(所需信息量=11 821)。

证据类型、等级与局限

  • 证据类型:Meta分析(纳入1项前瞻性随机对照试验和7项回顾性队列研究)。
  • 局限:异质性I=91%;试验序贯分析表明当前证据不足以得出结论(所需信息量=11 821);作者认为需更大样本量的前瞻性研究。

对床旁实践的改变

  • 作者认为,在联用VP和NE治疗的成人脓毒性休克患者中,先停VP可能导致更高的低血压发生率,但与死亡率或ICU住院时间无关。
  • 作者认为,需更大样本量的前瞻性研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Patients with septic shock in whom norepinephrine (NE) infusion alone is insufficient to raise blood pressure require the concomitant administration of vasopressin (VP). However, current guidelines do not advise clinicians as to which vasoactive agent to discontinue first once the patient's septic shock begins to resolve. Moreover, there is controversial data guiding clinicians on how to discontinue vasopressors for septic shock patients who are receiving a combination therapy of NE and VP.

METHODS: The PubMed, EMBASE, and Cochrane Central Register databases were searched from the database inception until October 18, 2018. Studies were limited to adult patients with septic shock who received concomitant NE and VP treatment, that included different orders of vasopressor discontinuation. The primary outcome was the incidence of hypotension. Overall mortality, ICU mortality, and length of stay (LOS) in the ICU were secondary outcomes. Sensitivity and subgroup analyses as well as trial sequential analysis were performed.

RESULTS: One prospective randomized controlled trial and seven retrospective cohort studies were included in present meta-analysis. Compared with discontinuing VP first, the incidence of hypotension was significantly lower when NE was discontinued first (odds ratio, OR 0.3, 95% confidence interval, CI 0.10 to 0.86, P = 0.02; I = 91%). No significant difference was detected in either overall mortality (OR 1.28, 95% CI 0.77 to 2.10, P = 0.34) or ICU mortality (OR 0.99, 95% CI 0.74 to 1.34, P = 0.96) between these two groups. Furthermore, ICU LOS was also evaluated in five studies, and no statistical significance was observed between the two groups with different orders in weaning vasopressors (mean difference 1.35, 95% CI -2.05 to 4.74, P = 0.44). The subgroup analyses suggested a significant association between hypotension and the practice of discontinuing VP first specifically in patients with a low usage rate of corticosteroids (odds ratio, OR 0.18, 95% confidence interval, CI 0.04 to 0.78, P = 0.02). The trial sequential analysis indicated a lack of sufficient evidence to draw conclusions from the current results (required information size = 11 821).

CONCLUSIONS: In adults with septic shock treated with concomitant VP and NE therapy, discontinuing VP first may lead to a higher incidence of hypotension but is not associated with mortality or ICU LOS. Further prospective studies with larger sample sizes are warranted.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Wu Z, Zhang S, Xu J, et al. Norepinephrine vs Vasopressin: Which Vasopressor Should Be Discontinued First in Septic Shock? A Meta-Analysis. Shock. 2020. PMID: 31008869. doi:10.1097/SHK.0000000000001345

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。